Meetings 

Keystone Nano (KN) is a developing two nanotechnology platforms to solve problems in the treatment of cancer. Both the Ceramide NanoLiposome (CNL) and the NanoJacket (NJ) precisely deliver therapies to tumors and address a $50 billion cancer therapeutic market where single products routinely exceed a billion in sales. KN’s technology was licensed from Penn State, and is distinct from all technology in development and has substantial technological advantages.  KN technology is an advanced stage of development is supported by considerable intellectual property and a successful multi-disciplinary commercialization team.

KN also creates custom nanoparticles for client companies designed to allow the creation of new products of value with highly unique features.  KN has worked with a wide range of pharmaceutical clients in this manner, and can do so in a milestone based manner.

Kimberly-Clark has developed an innovative transdermal drug delivery technology for Biologics.  The Biologic Transdermal System is designed to deliver large molecular weight biologics (demonstrated up to 150,000 Daltons) without a pump or other secondary device.   Kimberly-Clark has a rich heritage of providing innovative, high quality products for both consumer and B2B markets, including its $1.5 billion healthcare division that manufactures and markets a broad range of medical devices and medical supplies.

COMPANY PRESCRIPTION;

Kissei America, Inc is the US subsidiary of Kissei Pharma, one of the Japanese medium-sized pharma companies spending about 20% of revenue to its R&D effort. 

 Kissei is actively seeking for in-licensing, out-licensing and other business development opportunities for new drugs. 

For in-licensing, Kissei's primary focus is the territory of Japan and the therapeutic fields of urology, dialysis management/kidney disease, women's health, opthalmology and certain diseases with unmet medical needs.

For out-licensing, Kissei is actively seeking partners for several new chemical entities for the territory outside Japan.   Such out-licensing opportunities include agents for endometriosis/fibroid, diabetes, Parkinson's disease, gout/hyperuricemia and kidney stone in various stage of development.

PIPELINE PRODUCT;

1.       NAME ; Mitiglinide

DESCRIPTION     ; Mitiglinide is a short-acting insulin secretagogue for type II diabetes.  The  

                               agent has been already on the market in Japan and some Asian countries. 

                               The product is available for licensing in certain countries outside Asian

                                countries.

PHASE                    ; Market

INDICATION        ; Type II diabetes

2.       NAME ; Remoglifozin

DESCRIPTION     ; Remogliflozin is an SGLT2 inhibitor available for licensing in certain

                                countries.

PHASE                    ; Phase ll, lla, llb

INDICATION       ; Diabetes

3.       NAME; KUL-7211

DESCRIPTION     ; KUL-7211 is a beta 2/3 dual agonist, targeting the facilitation of kidney   

                                stone passage, available for licensing.

PHASE                   ;  Phase ll, lla, llb

INDICATION       ;  Kidney Stone

4.       NAME ; KLH-2109

DESCRIPTION         ; KLH-2109 is on oral GnRH antanogist available for licensing

PHASE                       ; Phase ll, lla, llb

INDICATION           ; Endometriosis, Uterine Fibroids

5.       NAME ; KGA-3235

DESCRIPTION         ; KGA-3235 is an SGLT1 inhibitor available for licensing in certain Asian

                                    countries.

PHASE                       ; Phase l

INDICATION           ;  Diabetes

6.       NAME ; KOM-1962

DESCRIPTION         ; KOM-1962 is a novel and improved COMT inhibitor available for

                                    licensing.

PHASE                       ; Preclinical

INDICATION           ; Parkinson’s Disease

7.       NAME ; KUX-0511

DESCRIPTION         ; KUX-0511 is the agent to be developed for gout and hyperuricemia

                                    through  decreasing  formation of uric acid and uricosuric effect, and                      

                                    available for  licensing.

PHASE                       ; Phase l

INDICATION           ; Gout and Hyperuricemia

Kowa Company, Ltd is a privately-held Japanese corporation headquartered in Nagoya. Since its establishment as a textile wholesaler in 1894, Kowa has grown into a multinational company with 48 affiliates around the world and has built a strong position in developing, manufacturing, marketing and trading products within a variety of businesses. Kowa started its pharmaceutical business in 1947, and has since built a strong presence in the Japanese prescription and OTC drug markets and it is growing rapidly overseas.

Areas of Interest

•      Cardiovascular

•      Metabolic Syndromes

•      Pain Management

•      Auto-inflammatory

•      Gastroenterological

Partnership Structures

•      Co-development

•      Co-commercialization

•      Licensing

•      Across all stages of development & commercialization

Laureate Biopharma is a leader in biopharmaceutical contract development and manufacturing with more than 30 years of experience. Our scientists are expert in process development and cGMP production of therapeutic proteins, including monoclonal antibodies and Fc-fusion proteins. In addition, our portfolio of services includes aseptic filling, cell line development, analytical and stability testing, and full regulatory support. Laureate has served a global client base from its Princeton, New Jersey facility since 1981. Laureate is a portfolio company of Saints Capital, LLC.

MacroGenics is a leader in the development of next-generation antibody therapeutics for the treatment of cancer, autoimmune disorders, and infectious disease. Using its proprietary platforms for cancer-stem cells, bi-specific antibodies (DARTs) and Fc-optimization, the company has generated a robust pipeline of clinical and pre-clinical programs. The company has multiple research and development collaborations with major pharmaceutical companies including Les Laboratoires Servier, Boehringer Ingelheim and Pfizer, Inc.

Mallinckrodt, the pharmaceuticals business of Covidien, is a vertically integrated leader in providing products used in diagnostic procedures and in the treatment of pain and related conditions.  Covidien announced last December that they are spinning off Mallinckrodt into a stand-alone company, a process that is expected to be completed in mid-2013.  Mallinckrodt is the largest US supplier, by prescription, of opioid pain medications and a leading manufacturer of active pharmaceutical ingredients. It is also the largest US supplier of the medical isotope technetium-99m and an industry leader in radiopharmaceuticals and contrast media and delivery systems.  Sales in 2011 were $2.0 billion. Please visit www. mallinckrodt.com to learn more about our business.  The company’s branded pharmaceuticals portfolio includes EXALGO® (hydromorphone HCl) Extended-Release Tablets (CII) and PENNSAID® (diclofenac sodium topical solution) 1.5% w/w.  In June 2012, Mallinckrodt entered into agreements with Horizon Pharma and Zogenix Inc. to co-promote their branded pharmaceuticals for rheumatoid arthritis and acute migraine, respectively.  In August 2012, the FDA approved the 32 mg tablet strength of EXALGO® (hydromorphone HCI) Extended-Release Tablets (CII).  Mallinckrodt is primarily pursuing acquisition or licensing deals for pharmaceuticals which are either in late stage development or are approved for commercialization.

MannKind’s patient-focused oral inhalation drug delivery technologies include a dry powder formulation capability coupled with an innovative, elegant, breath-powered delivery device. We are applying these technologies to facilitate partnered drug development programs for proprietary compounds.

MannKind has numerous collaborations across therapeutic areas that demonstrate the efficacy and safety of the technologies. Patients self-administer these dry powder formulations with small, easy-to-use, breath-powered inhalers. Following inhalation, drugs are absorbed very rapidly, essentially mimicking intra-arterial administration. MannKind has evaluated this versatile pulmonary drug delivery platform across multiple therapeutic areas, including diabetes, metabolism, respiratory disease, osteoporosis and pain.

For companies interested in exploring the feasibility of a Technosphere formulation using their own active pharmaceutical ingredient (API), MannKind offers a feasibility evaluation. These evaluations involve preparation and characterization of API/Technosphere formulations. These powders are tested for performance in MannKind’s inhalers. Additionally, MannKind works with the partner to test these powders in relevant nonclinical PK/PD models. These studies can often been completed within 6 months. 

MannKind seeks to establish partnerships to build therapeutic programs of significant clinical and commercial value. Whether through strategic alliances, licensing arrangements and/or research collaborations, MannKind's partnering approach is based on a flexible, creative methodology designed to establish mutually beneficial relationships that are positioned to capture upside potential beyond what either partner could achieve individually.

MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine. The U.S. Food and Drug Administration (FDA) reviewed the New Drug Application (NDA) for LEVADEX and on March 26, 2012, the Company received a Complete Response letter with respect to this NDA. MAP Pharmaceuticalshas entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. and Canada. The Company also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. Additional information about MAP Pharmaceuticals can be found athttp://www.mappharma.com.